Synaptogenix
New York, New York, United States · Artificial Intelligence, Biotechnology, Blockchain
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X
Key facts
- Headquarters
- New York, New York, United States
- Employees
- Unknown
- Industries
- Artificial Intelligence, Biotechnology, Blockchain
- Status
- Private
- Website
- www.synaptogen.com
- Company page
Recent activity at Synaptogenix
Synaptogenix funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Private Equity | $11.0M |
| Jun 2025 | Venture | $5.5M |
| Sep 2024 | Seed | $3.2M |
| Jun 2021 | Venture | $12.5M |
| Feb 2021 | Venture | $14.0M |
Leadership
- Robert Weinstein, Chief Financial Officer
- Daniel Alkon, President
- Daniel Alkon, President
- Robert Weinstein, Executive Officer
Verified email and direct lines for Synaptogenix’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to Synaptogenix
- Change Agents Corporation. · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Pathos AI · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Kordata Dynamics · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- TAO Synergies · Artificial Intelligence, Biotechnology, Blockchain, Cryptocurrency, Machine Learning
- Portage Biotech · Artificial Intelligence, Blockchain, Cryptocurrency, Health Care, Machine Learning
About Synaptogenix: questions and answers
What does Synaptogenix do?
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X
Where is Synaptogenix headquartered?
Synaptogenix is headquartered in New York, New York, United States.
Has Synaptogenix raised funding?
Yes. Fundz has recorded 5 funding events for Synaptogenix. The most recent, Private Equity of $11.0M, was in Oct 2025.
Who leads Synaptogenix?
Daniel Alkon is a President at Synaptogenix.
What is the latest news on Synaptogenix?
On Oct 13, 2025, TAO Synergies Inc. secures $11 million in a Private Equity round, backed by James Altucher and DCG, to further strategic investments in TAO tokens and the Bittensor ecosystem.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy